Fortress Biotech logo

Fortress BiotechNASDAQ: FBIO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

17 November 2011

Next earnings report:

07 November 2024

Last dividends:

N/A

Next dividends:

N/A
$43.35 M
-87%vs. 3y high
33%vs. sector
-vs. 3y high
-vs. sector
-47%vs. 3y high
63%vs. sector
-90%vs. 3y high
14%vs. sector

Price

after hours | Thu, 31 Oct 2024 22:00:23 GMT
$1.90-$0.12(-5.94%)

Dividend

No data over the past 3 years
$14.90 M$32.22 M
$14.90 M-$10.95 M

Analysts recommendations

Institutional Ownership

FBIO Latest News

Fortress Biotech to Participate in October 2024 Investor Conferences
globenewswire.com26 September 2024 Sentiment: POSITIVE

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following upcoming October 2024 investor conferences:

Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
zacks.com13 August 2024 Sentiment: NEUTRAL

Fortress Biotech (FBIO) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $1.32. This compares to loss of $3.60 per share a year ago.

Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewsWire07 September 2023 Sentiment: POSITIVE

MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 11:30 a.m. ET. The Company will also attend one-on-one meetings during the conference.

Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research15 May 2023 Sentiment: NEGATIVE

Fortress Biotech (FBIO) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.18 per share a year ago.

What type of business is Fortress Biotech?

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

What sector is Fortress Biotech in?

Fortress Biotech is in the Healthcare sector

What industry is Fortress Biotech in?

Fortress Biotech is in the Biotechnology industry

What country is Fortress Biotech from?

Fortress Biotech is headquartered in United States

When did Fortress Biotech go public?

Fortress Biotech initial public offering (IPO) was on 17 November 2011

What is Fortress Biotech website?

https://www.fortressbiotech.com

Is Fortress Biotech in the S&P 500?

No, Fortress Biotech is not included in the S&P 500 index

Is Fortress Biotech in the NASDAQ 100?

No, Fortress Biotech is not included in the NASDAQ 100 index

Is Fortress Biotech in the Dow Jones?

No, Fortress Biotech is not included in the Dow Jones index

When was Fortress Biotech the previous earnings report?

No data

When does Fortress Biotech earnings report?

The next expected earnings date for Fortress Biotech is 07 November 2024